Survival, neurocognitive function, and health-related quality of life outcomes after rituximab-methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final Results of the HOVON 105 / ALLG NHL 24 Study
Jacoline E C Bromberg*, Samar Issa, Bronno van der Holt, Matthijs van der Meulen, Linda Dirven, Monique C Minnema, Tatjana Seute, Marc Durian, Gavin Cull, Marjolein W M van der Poel, Wendy B C Stevens, Josee M Zijlstra, Dieta Brandsma, Marcel Nijland, Kylie D Mason, Aart Beeker, Martine C J Abrahamse-Testroote, Martin J van den Bent, Daphne de Jong, Jeanette K Doorduijn
Research output: Contribution to journal › Article › Academic › peer-review
Fingerprint
Dive into the research topics of 'Survival, neurocognitive function, and health-related quality of life outcomes after rituximab-methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final Results of the HOVON 105 / ALLG NHL 24 Study'. Together they form a unique fingerprint.